Sintilimab in combination with anlotinib in non-small cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study

被引：0

作者：

Chen, K. ^{[1
]}

Fan, Y. ^{[1
]}

机构：

[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Oncol, Canc Hosp, Hangzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.02.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

21P

引用

页码：S39 / S39

页数：1

共 50 条

[1] Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
Fan, Y.
Chen, K.
Xu, Y.
Huang, Z.
Hong, W.
Li, H.
Xie, F.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S352 - S352
[2] Anlotinib combination with docetaxol for patients with previously treated advanced non-small cell lung cancer: A phase II, single-arm trial
Chen, X.
Shen, J.
Li, X.
Yang, S.
Xia, B.
Wang, B.
Wang, J.
Zheng, S.
Zhao, P.
Ma, S.
ANNALS OF ONCOLOGY, 2020, 31 : S877 - S877
[3] Anlotinib combined with radiotherapy in locally advanced non-small cell lung cancer (LANSCLC): A prospective, single-arm, phase II study
Ning, P.
Chang, H.
Zhang, J.
Rong, P.
Liu, H.
ANNALS OF ONCOLOGY, 2021, 32 : S944 - S944
[4] Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial
Chen, Kaiyan
Xu, Yanjun
Huang, Zhiyu
Yu, Xiaoqing
Hong, Wei
Li, Hui
Xu, Xiaoling
Lu, Hongyang
Xie, Fajun
Chen, Jun
Xu, Youzu
Fan, Yun
CANCER MEDICINE, 2023, 12 (19): : 19460 - 19470
[5] Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China
Xiao Han
Jun Guo
Xiaoyong Tang
Hui Zhu
Dongyuan Zhu
Xiqin Zhang
Xiangjiao Meng
Ying Hua
Zhongtang Wang
Yan Zhang
Wei Huang
Linlin Wang
Shuanghu Yuan
Pingliang Zhang
Heyi Gong
Yulan Sun
Yingjie Zhang
Zengjun Liu
Zhehai Wang
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1443 - 1451
[6] Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China
Han, Xiao
Guo, Jun
Tang, Xiaoyong
Zhu, Hui
Zhu, Dongyuan
Zhang, Xiqin
Meng, Xiangjiao
Hua, Ying
Wang, Zhongtang
Zhang, Yan
Huang, Wei
Wang, Linlin
Yuan, Shuanghu
Zhang, Pingliang
Gong, Heyi
Sun, Yulan
Zhang, Yingjie
Liu, Zengjun
Wang, Zhehai
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (04) : 1443 - 1451
[7] Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study
Lu, Shun
Zhou, Jian-Ying
Niu, Xiao-Min
Zhou, Jian-Ya
Jian, Hong
Yin, Hong-Yan
Guan, Sha
Wang, Lin-Fang
Li, Ke
He, James
Su, Wei-Guo
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) : 839 - +
[8] Combining sintilimab with anlotinib as second-line or later therapy in patients with extensive-disease small cell lung cancer: A prospective, single-arm, phase II trial
Shuxiang, M.
Zhen, H.
Lili, W.
Yufeng, W.
Sen, Y.
Haiyang, C.
Yingxi, W.
Wang, Q.
ANNALS OF ONCOLOGY, 2021, 32 : S1402 - S1402
[9] A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
Hisashi Tanaka
Kageaki Taima
Takeshi Morimoto
Yoshihito Tanaka
Masamichi Itoga
Kunihiko Nakamura
Akihito Hayashi
Mika Kumagai
Hideo Yasugahira
Megumi Mikuniya
Koichi Okudera
Shingo Takanashi
Sadatomo Tasaka
BMC Cancer, 17
[10] Single-Arm Phase II Study of Nab-Paclitaxel for Patients with Chemorefractory Non-Small Cell Lung Cancer
Tanaka, Hisashi
Taima, Kageaki
Morimoto, Takeshi
Tanaka, Yoshihito
Itoga, Masamichi
Nakamura, Kunihiko
Hayashi, Akihito
Kumagai, Mika
Yasugahira, Hideo
Mikuniya, Megumi
Okudera, Koichi
Takanashi, Shingo
Tasaka, Sadatomo
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S922 - S922

← 1 2 3 4 5 →